

To: Medical Staff, House Staff, Patient Care Centers, and Outpatient Clinics

From: Jeremy Segal, MD, PhD, Vice Chair, Genomic Pathology, Medical Director, Molecular Diagnostics Laboratory

Carrie Fitzpatrick, PhD, FACMG, Co-Director, Cytogenetics Laboratory, Assistant Medical Director, Molecular Diagnostics Laboratory

Date: 8/18/2025

Subject: New JAK2 Reflex to CALR Test

Effective Date: 8/18/2025

Laboratory Section: Molecular Diagnostics

Description/Summary:

Effective Monday, August 18, 2025, a new JAK2 Reflex to CALR test is available to order in Epic.

The JAK2 (Janus Kinase 2) genotyping assay is performed in-house for diagnoses and management of myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, primary myelofibrosis and other myeloproliferative disorders.

The CALR assay is performed by Mayo Clinic Laboratories. It detects insertions and deletion-type mutations in exon 9 of the *CALR* gene and is useful in distinguishing between reactive thrombocytosis and leukocytosis versus a myeloproliferative neoplasm (MPN), especially essential thrombocythemia (ET) and primary myelofibrosis (PMF). It is highly informative in cases in which JAK2 testing is negative.

With JAK2 Reflex to CALR test option, a negative JAK2 results (V617F Mutation is not detected) will automatically reflex to order the Mayo CALR test. The standalone JAK2 V617F test (test code LABMDJAK2) is still available to order, and there are no changes to this test.

There are no changes to the CPT codes, turnaround times or specimen requirements for either testing option.

Test Name: **JAK2 Reflex to CALR**

Test Code: **LABMDJAKR**

Questions: If there are any questions regarding the change, test requirements or ordering, please contact:

- Carrie Fitzpatrick, PhD, cfitzpat@bsd.uchicago.edu
- Bekim Ameti, Bekim.Ameti@uchicagomedicine.org